These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8549307)

  • 61. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Ross JJ; Worthington MG; Gorbach SL
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12097545
    [No Abstract]   [Full Text] [Related]  

  • 62. Prescribing considerations in fluoroquinolone therapy.
    Gentry LO
    Pharmacotherapy; 1993; 13(2 Pt 2):39S-44S. PubMed ID: 8474937
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Bacteriology in community-acquired respiratory pathology].
    Weber P
    Presse Med; 1998 Mar; 27(11):546-8. PubMed ID: 9767971
    [No Abstract]   [Full Text] [Related]  

  • 64. Ofloxacin in lower respiratory tract infections.
    Hänninen P
    Drugs; 1987; 34 Suppl 1():179-80. PubMed ID: 3481320
    [No Abstract]   [Full Text] [Related]  

  • 65. New concepts in antimicrobial therapy for emergency department infections.
    Talan DA
    Ann Emerg Med; 1999 Oct; 34(4 Pt 1):503-16. PubMed ID: 10532910
    [No Abstract]   [Full Text] [Related]  

  • 66. A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections.
    Sawae Y; Ninomiya K; Takaki K; Shimono N; Misumi H; Okada K
    Drugs; 1995; 49 Suppl 2():430-2. PubMed ID: 8549390
    [No Abstract]   [Full Text] [Related]  

  • 67. Open-label, multicentre, emergency-use study of clinafloxacin (CI-960) in the treatment of patients with serious life-threatening infections.
    Shah P; Trostmann U; Tack K
    Int J Antimicrob Agents; 2002 Mar; 19(3):245-8. PubMed ID: 11932150
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical experience with ofloxacin (DL 8280) in the therapy of various infections: preliminary report.
    Cristiano P; Leonessa V; Morelli G; Briante V; Paradisi F; Altucci P
    Infection; 1986; 14 Suppl 4():S307-8. PubMed ID: 3546152
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections.
    Soejima R; Niki Y; Kishomoto T; Kimura M; Kubota Y
    Drugs; 1995; 49 Suppl 2():257-9. PubMed ID: 8549323
    [No Abstract]   [Full Text] [Related]  

  • 70. Efficacy of ofloxacin in lower respiratory tract infections bacteriologically diagnosed by fibreoptic-bronchoscopy aspirate culture.
    Tomasic-Cvitanovic S; Kotaraki Z
    Drugs; 1995; 49 Suppl 2():446-7. PubMed ID: 8549395
    [No Abstract]   [Full Text] [Related]  

  • 71. Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
    Watanabe K; Yoshida M; Ishibashi T; Yamada H; Kido M; Hirose T; Maeda F; Matsuzaki Y
    Drugs; 1995; 49 Suppl 2():448-50. PubMed ID: 8549396
    [No Abstract]   [Full Text] [Related]  

  • 72. Clinical evaluation of ofloxacin in lower respiratory tract infections.
    Kobayashi H
    Infection; 1986; 14 Suppl 4():S279-82. PubMed ID: 3469163
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
    Kawahara S; Watanabe Y; Matsuka Y; Sato T; Takahashi K
    Drugs; 1995; 49 Suppl 2():414-5. PubMed ID: 8549382
    [No Abstract]   [Full Text] [Related]  

  • 74. Role of newer fluoroquinolones in lower respiratory tract infections.
    Lode H; Allewelt M
    J Antimicrob Chemother; 2002 May; 49(5):709-12. PubMed ID: 12003962
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.
    Grassi C; Gialdroni Grassi G; Mangiarotti P
    Drugs; 1987; 34 Suppl 1():80-2. PubMed ID: 3325260
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?].
    Roig J; Martínez Benazet J; Casal J
    Arch Bronconeumol; 2002 Nov; 38(11):547; author reply 547-8. PubMed ID: 12435323
    [No Abstract]   [Full Text] [Related]  

  • 77. Ofloxacin in cystic fibrosis.
    Meyer H
    Drugs; 1987; 34 Suppl 1():177-9. PubMed ID: 3481319
    [No Abstract]   [Full Text] [Related]  

  • 78. Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.
    Sufarlan AW; Zainudin BM; Pit S; Ishak I
    Drugs; 1995; 49 Suppl 2():442-5. PubMed ID: 8549394
    [No Abstract]   [Full Text] [Related]  

  • 79. [Clinical efficacy of lomefloxacin for associated infection in patients with hematological diseases].
    Suzuki T; Sasada M; Okuma M; Fukuhara S; Yasuda N; Amano H; Kanachi K; Ohno T; Kawasaki T; Yumoto Y
    Kansenshogaku Zasshi; 1997 Feb; 71(2):143-52. PubMed ID: 9077072
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Failure of infection control in intensive care units: can sucralfate improve the situation?
    Weinstein RA
    Am J Med; 1991 Aug; 91(2A):132S-134S. PubMed ID: 1882900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.